Andere talen Race Oncology Limited

Aandelen

Beurs gesloten - Australian S.E. Andere beurzen 08:10:56 28-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,405 ^AUD	-3,77%		-5,70%	+67,26%

26/03	Race Oncology ontvangt analysecertificaat voor RC220; aandelen stijgen bijna 6%	MT
06/03	Race Oncology zegt dat studie de werkzaamheid van het hoofdproduct bij de behandeling van bloedkanker aantoont	MT

Race Oncology's breakthrough in cancer cell treatment	15/05
Race Oncology Obtains Certificate of Analysis for RC220; Shares Up Almost 6%	26/03
Race Oncology Limited(ASX:RAC) dropped from S&P/ASX All Ordinaries Index	18/03
Race Oncology Says Study Shows Lead Asset's Efficacy in Blood Cancer Treatment	06/03
Race Oncology looks to accelerate clinical development of bisantrene	28/02
Race Oncology Widens Loss in Fiscal H1	28/02
Race Oncology Limited Reports Earnings Results for the Half Year Ended December 31, 2023	27/02
Race Oncology appoints Dr Daniel Tillett as CEO	23/11
Race Oncology Names CEO; Shares Jump 5%	22/11
Race Oncology Limited Appoints Daniel Tillett as Chief Executive Officer	21/11
Race Oncology highlights impressive bisantrene clinical data	07/11
Race Oncology kicks off safety studies for RC220	09-10-23
Race Oncology Initiates Toxicology, Safety Pharmacology Studies of Chemotherapy Drug	05-10-23
Race Oncology Limited(ASX:RAC) dropped from S&P Global BMI Index	18-09-23
Race Oncology Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30-08-23
Race Oncology Limited Announces Board Changes	22-08-23
Race Oncology at the heart of cancer care	09-08-23
Race Oncology announces deal with manufacturer Ardena to develop companyÃ¢€™s new IV formulation RC220	19-07-23
Race Oncology Secures More R&D Tax Rebate for Fiscal Year 2022; Shares Rise 4%	13-07-23
Race Executes Agreement with Ardena for GMP Manufacturing of RC220	12-07-23

Geen resultaten voor deze zoekopdracht